What Transformation Has the Hepatocellular Carcinoma Drugs Market Undergone?
The hepatocellular carcinoma drugs market has seen considerable growth due to a variety of factors.
•Significant growth has been witnessed in the market size of hepatocellular carcinoma drugs in the last few years. The market is projected to expand from a value of $1.16 billion in 2024 to $1.27 billion in 2025, indicating a compound annual growth rate (CAGR) of 9.1%.
The previously observed growth can be credited to factors such as rising disease prevalence, breakthroughs in cancer research, enhancements in the global healthcare infrastructure, regulatory approvals, and efforts towards increasing awareness and early diagnosis.
How Will The Hepatocellular Carcinoma Drugs Market Size Evolve In The Foreseeable Future?
The hepatocellular carcinoma drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The market for drugs treating hepatocellular carcinoma is anticipated to witness robust growth in the upcoming years, reaching an estimated value of "$1.77 billion by 2029 with a compound annual growth rate (CAGR) of 8.8%.
The projected growth during the forecast period can be credited to advancements in targeted therapies, a rise in the aging population, personalization trends in healthcare, and the worldwide enlargement of treatment availability. Noteworthy trends expected during the forecast period involve the access to groundbreaking therapies, patient-focused care, advancements in regulatory guidelines, strategies to combat drug resistance, and cooperative research initiatives.
Which Key Drivers Are Propelling The Hepatocellular Carcinoma Drugs Market's Growth?
The increasing prevalence of hepatocellular carcinoma is anticipated to drive the hepatocellular carcinoma drug market's expansion in the future. Hepatocellular carcinoma (HCC) represents the most prevalent form of liver cancer, a primary malignancy of the liver. This condition originates from hepatocytes, the predominant liver cells. The majority of HCC instances are attributed to hepatitis B or C infections, or cirrhosis. The rising prevalence of hepatocellular carcinoma necessitates a higher demand for effective drugs to combat this disease. For example, data from the American Cancer Society, Inc., a voluntary health organization dedicated to eradicating cancer across the US, revealed that the number of liver cancer cases among women diagnosed in the country escalated from 12,660 in 2022 to 13,230 in 2023. This escalation in hepatocellular carcinoma prevalence is propelling the hepatocellular carcinoma drug market's growth.
What Are The Key Segments Within The Global Hepatocellular Carcinoma Drugs Market?
The hepatocellular carcinoma drugs market covered in this report is segmented –
1) By Type: Brachytherapy, Chemotherapy
2) By Drug Class: PD-1/PD-L1 Inhibitors, Tyrosine Kinase Inhibitors
3) By End User: Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers
Subsegments:
1) By Brachytherapy: Radioactive Seed Implants, Balloon-Activated Brachytherapy, SIRT (Selective Internal Radiation Therapy)
2) By Chemotherapy: Systemic Chemotherapy, Targeted Therapy Agents, Combination Chemotherapy Regimens, Adjuvant Chemotherapy
Pre-Book The Hepatocellular Carcinoma Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Hepatocellular Carcinoma Drugs Market?
Leading firms in the hepatocellular carcinoma drugs market are increasingly focusing on the creation of laboratory-made molecules like monoclonal antibodies (mAb) to expand their clientele, boost sales, and raise revenue. Monoclonal antibodies (mAb) are laboratory-generated molecules designed to replicate the immune system's power to combat harmful pathogens such as bacteria or viruses. For instance, in October 2022, UK-based pharmaceutical and biotech firm, AstraZeneca PLC, proclaimed the approval of Imjudo (tremelimumab) in conjunction with Imfinzi (durvalumab) by the US Food and Drug Administration (FDA) for the treatment of adult patients with hepatocellular carcinoma (HCC). Imfinzi (durvalumab) is a unique human monoclonal antibody that efficiently binds with PD-L1 protein. This binding process obstructs the interaction among PD-L1, PD-1, and CD80 proteins, impairing the tumor's ability to evade the immune system and facilitating the removal of immune response inhibitions. Moreover, Imjudo (tremelimumab) is a human monoclonal antibody purposedly designed to aim at the function of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Imjudo operates by blocking the activity of CTLA-4, thus encouraging T-cell activation, priming the immune response against cancer, and promoting cancer cell death.
Who Are the Key Players in the Hepatocellular Carcinoma Drugs Market?
Major companies operating in the hepatocellular carcinoma drugs market include:
• AbbVie Inc.
• Amgen Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• Eisai Co.Ltd.
• Eli Lilly and Company
• Johnson & Johnson
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• F. Hoffmann-La Roche Ltd
• Gilead Sciences Inc.
• Exelixis Inc.
• Ipsen Pharma Biotech SAS
• AstraZeneca plc
• BeiGene Ltd.
• Ono Pharmaceutical Co. Ltd.
• Roche Holdings AG
• Sanofi S.A.
• Astellas Pharma Inc.
• Daiichi Sankyo Company Limited
• Otsuka Pharmaceutical Co. Ltd.
• Kyowa Kirin Co. Ltd.
• Sumitomo Dainippon Pharma Co. Ltd.
• Hengrui Medicine Co. Ltd.
• CSPC Pharmaceutical Group Limited
• Hutchison China MediTech Limited
• Jiangsu Hengrui Medicine Co. Ltd.
What are the Regional Insights into the Hepatocellular Carcinoma Drugs Market?
North America was the largest region in the hepatocellular carcinoma drug market in 2024. The regions covered in the hepatocellular carcinoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
